1. Home
  2. JJSF vs RVPH Comparison

JJSF vs RVPH Comparison

Compare JJSF & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JJSF
  • RVPH
  • Stock Information
  • Founded
  • JJSF 1971
  • RVPH 2006
  • Country
  • JJSF United States
  • RVPH United States
  • Employees
  • JJSF N/A
  • RVPH N/A
  • Industry
  • JJSF Specialty Foods
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • JJSF Consumer Staples
  • RVPH Health Care
  • Exchange
  • JJSF Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • JJSF N/A
  • RVPH 32.8M
  • IPO Year
  • JJSF N/A
  • RVPH N/A
  • Fundamental
  • Price
  • JJSF $118.24
  • RVPH $0.37
  • Analyst Decision
  • JJSF Buy
  • RVPH Strong Buy
  • Analyst Count
  • JJSF 2
  • RVPH 5
  • Target Price
  • JJSF $142.50
  • RVPH $9.00
  • AVG Volume (30 Days)
  • JJSF 186.8K
  • RVPH 2.6M
  • Earning Date
  • JJSF 08-04-2025
  • RVPH 08-13-2025
  • Dividend Yield
  • JJSF 2.64%
  • RVPH N/A
  • EPS Growth
  • JJSF N/A
  • RVPH N/A
  • EPS
  • JJSF 3.89
  • RVPH N/A
  • Revenue
  • JJSF $1,585,410,000.00
  • RVPH N/A
  • Revenue This Year
  • JJSF $3.64
  • RVPH N/A
  • Revenue Next Year
  • JJSF $3.68
  • RVPH N/A
  • P/E Ratio
  • JJSF $30.40
  • RVPH N/A
  • Revenue Growth
  • JJSF 0.49
  • RVPH N/A
  • 52 Week Low
  • JJSF $109.71
  • RVPH $0.30
  • 52 Week High
  • JJSF $180.80
  • RVPH $4.28
  • Technical
  • Relative Strength Index (RSI)
  • JJSF 54.50
  • RVPH 30.28
  • Support Level
  • JJSF $111.30
  • RVPH $0.35
  • Resistance Level
  • JJSF $120.34
  • RVPH $0.83
  • Average True Range (ATR)
  • JJSF 3.14
  • RVPH 0.07
  • MACD
  • JJSF 0.85
  • RVPH -0.04
  • Stochastic Oscillator
  • JJSF 79.50
  • RVPH 11.32

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: